Anandamide Analog.

PEA is a fatty acid amide broken down by the same FAAH enzyme, so it competes for degradation and lets anandamide-type molecules persist longer. This competitive sparing is the basis of the entourage effect.

Oleamide is another endogenous fatty acid amide and a competing substrate for fatty acid amide hydrolase. Its presence slows the breakdown of the anandamide pool through simple substrate competition.

Long-chain fatty acids are incorporated into the N-acylphosphatidylethanolamine pool that endocannabinoid-like molecules are cleaved from, and DHA gives rise to its own ethanolamide. Dietary fatty acid composition therefore shapes the size and makeup of that signalling pool.

Linoleic acid is the dietary precursor of arachidonic acid, which forms the fatty acid backbone of anandamide itself. Intake of the parent fatty acid sets the substrate available for that synthesis.

Cannabidiol slows anandamide breakdown two ways: it inhibits fatty acid amide hydrolase and it competes for the fatty acid binding proteins that carry anandamide to that enzyme. The result is a longer-lived pool of endogenous anandamide rather than a new agonist. The human trial available here measured self-reported sleep quality and immune cell markers with cannabidiol alone, so the mechanism is well described while the joint effect is not.

Anandamide is arachidonoyl ethanolamide, so the arachidonic acid esterified in membrane phospholipid is literally the acyl chain the pathway uses. Membrane fatty acid composition therefore sets the size of the pool available for release. This is a supply relationship in settled lipid biochemistry, not a demonstrated dose response.

The enzymes that build and break N-acylethanolamides accept several fatty acyl chains, so eicosapentaenoic acid is incorporated into its own ethanolamide and competes for the same machinery. Raising long-chain omega-3 intake shifts the mix of ethanolamides made rather than simply adding to it. Which direction that goes for anandamide specifically has been measured in tissue, not in a clinical endpoint.

Phosphatidylethanolamine, the backbone that N-acylphosphatidylethanolamine is built from, is generated in part by decarboxylation of phosphatidylserine. That puts phosphatidylserine two steps upstream of the membrane precursor these amides are released from. It is a pathway position, and no trial has tested whether supplying it changes ethanolamide release.

Phosphatidylcholine serves twice here: it feeds the membrane phospholipid pool that carries acylethanolamide precursors, and as an emulsifier it disperses poorly water soluble lipid amides in the gut. The second role is the one that matters to a formulator. Neither has been quantified against a plain powder in a human comparison.

Lecithin emulsifies fatty acid amides that otherwise sit as poorly wetted powder in gastric fluid. For this class, whether the material dissolves is the main variable a formula can influence. Sunflower-derived lecithin is chosen where a soy-free label is wanted.

Medium-chain triglycerides dissolve fatty acid amides and empty from the stomach quickly, which is why softgels are a common format for this class. The pairing is sound lipid chemistry. No head-to-head measurement against a dry powder is available here, so no size can be put on it.

Phosphatidylethanolamine N-methyltransferase converts phosphatidylethanolamine into phosphatidylcholine using S-adenosylmethionine, and dietary choline changes how much of that route is used. Since phosphatidylethanolamine is the precursor these amides come from, choline status touches the pool indirectly. The direction and size of that effect in people has not been measured, hence early confidence.

Anandamide activates TRPV1 as well as cannabinoid receptors, and capsaicin is the reference agonist at that channel. Two agonists at one channel is a genuine pharmacological overlap, with the caveat that sustained TRPV1 agonism desensitises the channel rather than driving it harder. The overlap is receptor-level and has not been studied as a supplement combination.

Melatonin acts on circadian timing through MT1 and MT2 receptors, a completely separate route from endocannabinoid signalling. In a night-time formula the two are combined for a shared purpose rather than a shared mechanism, so any joint drowsiness effect is additive by intent. Nothing here measures the combination, and a stacked sedative effect is worth flagging in either direction.

Valerian constituents act on GABAergic signalling, which does not overlap with acylethanolamide pathways. The reason to record the pairing is the additive drowsiness that two sedating ingredients can produce together. That is a formulation caution stated at early confidence, not a benefit claim.

L-theanine changes glutamatergic and GABAergic tone and shows up in the same evening formulas as fatty acid amides. The mechanisms do not touch, so the pairing is about intent and about the possibility of stacked drowsiness. No combination study speaks to it.

Honokiol and magnolol act at GABA-A, a route unrelated to endocannabinoid signalling. Combined with a sedating lipid amide the practical point is cumulative drowsiness. Recorded at early confidence as a formulation note.

Apigenin has low-affinity activity at the benzodiazepine site of GABA-A and is a common evening flavone. Nothing links it mechanistically to acylethanolamide metabolism. The pairing belongs on the page as an additive drowsiness consideration rather than a synergy claim.

Caffeine blocks adenosine receptors and raises arousal, working against the sleep-onset purpose of this class. There is no shared enzyme or receptor; the conflict is at the level of net effect. It earns a row because a stimulant taken close to an evening dose can cancel what the formula was built for.